FIELD: biology, medicine.
SUBSTANCE: invention reports about identification of new cytostatic factor of natural origin eliciting immunoregulatory and antitumor properties. This factor can be isolated from nucleus-containing erythroid cells. Factor shows thermostability, it resistant to enzymatic proteolysis and to effect of lipase and phospholipase but sensitive to treatment with neuraminidase, its molecular mass is about 0.5 kDa or less. The identified factor can be used in treatment of allergic, autoimmune and tumor diseases. Invention provides preparing the product no eliciting antigenic and allergic properties with retention of its effectiveness in prolonged storing.
EFFECT: improved preparing method, valuable medicinal properties of factor.
7 cl, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
HEMOPROTECTIVE AGENT | 2018 |
|
RU2696586C1 |
ANTIMUTAGENIC AGENT | 2000 |
|
RU2189232C2 |
HEMOPROTECTIVE AGENT | 2019 |
|
RU2725135C1 |
METHOD OF TREATING ONCOLOGICAL DISEASES | 2012 |
|
RU2490028C1 |
METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 |
|
RU2421720C2 |
METHOD OF TREATING ONCOLOGICAL DISEASES IN EXPERIMENT | 2007 |
|
RU2396967C2 |
HEMOSTIMULATING AGENT | 2017 |
|
RU2647833C1 |
BIOMEDICAL CELL PRODUCT, METHOD FOR ITS PRODUCTION AND APPLICATION | 2018 |
|
RU2741769C2 |
MEDICATION OF STIMULATION OF STEM CELL PRODUCTION IN BONE MARROW | 2007 |
|
RU2410116C2 |
TREATMENT METHOD FOR HEMATOPOIETIC ERYTHROID LINEAGE DEPRESSION IN CYTOSTATIC MYELOSUPRESSION | 2008 |
|
RU2364398C1 |
Authors
Dates
2004-08-10—Published
2002-07-09—Filed